Table 2.
Effect of HLA match on transplant outcomes (N=304)*
Clinical endpoint | HLA Match | N | Events | Hazard ratio | 95% CI | p |
---|---|---|---|---|---|---|
OS | 11/12 | 166 | 50 | |||
10/12 | 65 | 30 | 1.68 | 1.07 -2.64 | 0.02 | |
12/12 | 73 | 32 | 1.61 | 1.03 -2.51 | 0.04 | |
EFS | 11/12 | 166 | 64 | |||
10/12 | 65 | 33 | 1.47 | 0.96-2.24 | 0.07 | |
12/12 | 73 | 40 | 1.66 | 1.12-2.47 | 0.01 | |
CIR | 11/12 | 166 | 30 | |||
10/12 | 65 | 14 | 1.25 | 0.66-2.35 | 0.50 | |
12/12 | 73 | 24 | 2.02 | 1.18-3.47 | 0.01 | |
NRM | 11/12 | 166 | 34 | |||
10/12 | 65 | 19 | 1.48 | 0.84-2.59 | 0.17 | |
12/12 | 73 | 16 | 1.09 | 0.61-1.96 | 0.76 | |
Acute GvHD II-IV | 11/12 | 165 | 66 | |||
10/12 | 65 | 35 | 1.43 | 0.95-2.15 | 0.09 | |
12/12 | 72 | 27 | 0.92 | 0.59-1.44 | 0.72 | |
Acute GvHD III-IV | 11/12 | 165 | 22 | |||
10/12 | 65 | 14 | 1.57 | 0.79-3.13 | 0.20 | |
12/12 | 73 | 11 | 1.14 | 0.55-2.36 | 0.73 | |
Chronic GvHD | 11/12 | 164 | 119 | |||
10/12 | 65 | 48 | 1.19 | 0.84-1.69 | 0.32 | |
12/12 | 73 | 47 | 0.84 | 0.60-1.19 | 0.33 |
All models are multivariable and adjusted for age (<58 vs. ≥58) and disease risk (high, intermediate, low/non-malignant). Patients with incomplete clinical data or with disease risk of other were excluded.